Predict your next investment

HEALTHCARE | Biotechnology

See what CB Insights has to offer

Founded Year




Total Raised


Date of IPO


Market Cap


About NOXXON Pharma

NOXXON Pharma is a clinical-stage biopharmaceutical company whose core focus is on improving cancer treatment by targeting the tumor microenvironment. NOXXON's goal is to significantly enhance the effectiveness of cancer treatments including immuno-oncology approaches (such as immune checkpoint inhibitors) and current standards of care (such as chemotherapy and radiotherapy.)

NOXXON Pharma Headquarter Location

Max-Dohrn-Strasse 8-10

Berlin, 10589,


+49 30 726247 0

Latest NOXXON Pharma News

NOXXON Provides Progress Update on the Expansion Arms of the Phase 1/2 GLORIA Trial With NOX-A12 in Brain Cancer Patients

Jan 7, 2022

01/07/2022 | 02:01am EST Message : Additional expansion arm with NOX-A12, radiotherapy and pembrolizumab approved by competent authority Regulatory News: NOXXON Pharma N.V. (Euronext Growth Paris: ALNOX) (Paris:ALNOX), a biotechnology company focused on improving cancer treatments by targeting the tumor microenvironment (TME), announced today that the Data Safety Monitoring Board (DSMB) positively evaluated safety data from the initial four weeks of treatment of the first patient enrolled in the GLORIA clinical trial expansion arm with NOX-A12 combined with radiotherapy and bevacizumab. The DSMB concluded that it is safe and appropriate to continue recruitment of five additional remaining patients into this arm according to the study protocol. NOXXON also announced that the German Federal Institute for Drugs and Medical Devices (BfArM, Bundesinstitut für Arzneimittel und Medizinprodukte) approved the third expansion arm of the GLORIA clinical trial in which patients will receive the PD-1 immune checkpoint inhibitor pembrolizumab in combination with NOX-A12 and radiotherapy. Aram Mangasarian, CEO of NOXXON, commented: "The three arms in the expansion of our Phase 1/2 study of NOX-A12 are supported by the clinical data from the GLORIA trial and are designed to explore the potential for improved benefits for patients with brain tumors. The combination with the anti-PD-1 inhibitor pembrolizumab is of particular interest as we expect this combination therapy to unlock a stronger and more durable immune response against the tumor. This is based on our previous observation that NOX-A12 drives infiltration of activated cytotoxic immune cells into brain tumor tissue. We plan to use clinical data from the expansion arms to support our future pivotal glioblastoma study." The GLORIA Phase 1/2 clinical trial evaluates the safety and efficacy of NOX-A12 combined with radiotherapy in newly diagnosed brain cancer (glioblastoma) patients with unmethylated MGMT promoter. Three expansion arms, each intending to enrol six patients, will evaluate the benefit of NOX-A12 in other therapeutic settings: Arm A: NOX-A12 with radiotherapy in patients with complete tumor resection Arm B: NOX-A12 with radiotherapy and bevacizumab in patients with incomplete tumor resection Arm C: NOX-A12 with radiotherapy and pembrolizumab in patients with incomplete tumor resection. About NOXXON NOXXON’s oncology-focused pipeline acts on the tumor microenvironment (TME) and the cancer immunity cycle by breaking the tumor protection barrier and blocking tumor repair. By neutralizing chemokines in the TME, NOXXON’s approach works in combination with other forms of treatment to weaken tumor defenses against the immune system and enable greater therapeutic impact. NOXXON’s lead program NOX-A12 has delivered final top-line data from a Keytruda® combination trial in metastatic colorectal and pancreatic cancer patients published at the ESMO conference in September 2020 and in July 2021 the company announced its Phase 2 study, OPTIMUS, to further evaluate safety and efficacy of NOX-A12 in combination with Merck’s Keytruda® and two different chemotherapy regimens as second-line therapy in patients with metastatic pancreatic cancer. NOXXON is also studying NOX-A12 in brain cancer in combination with radiotherapy which has been granted orphan drug status in the US and EU for the treatment of certain brain cancers. GLORIA, a trial of NOX-A12 in combination with radiotherapy in newly diagnosed brain cancer patients who will not benefit clinically from standard chemotherapy has delivered interim data from the first two cohorts showing consistent tumor reductions and objective tumor responses. The company’s second clinical-stage asset NOX-E36 is a Phase 2 TME asset targeting the innate immune system. NOXXON plans to test NOX‑E36 in patients with solid tumors. Further information can be found at: . Keytruda® is a registered trademark of Merck Sharp & Dohme Corp.

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing NOXXON Pharma

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

NOXXON Pharma is included in 3 Expert Collections, including Cancer.



4,784 items

Pharmaceutical and biotechnology companies with cancer therapy drug candidates.


Biopharma Tech

15,532 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.


Regenerative Medicine

1,818 items

Regenerative medicine refers to the process of activating, replacing, engineering or regenerating human genetic material, cells, tissues or organs to restore normal function. It also includes bioengineered tissues used for in vitro testing (e.g. organ-on-a-chip, organoids).

NOXXON Pharma Patents

NOXXON Pharma has filed 39 patents.

The 3 most popular patent topics include:

  • Chemokine receptors
  • Cytokines
  • Molecular biology
patents chart

Application Date

Grant Date


Related Topics




Molecular biology, DNA replication, Small nuclear RNA, Biotechnology, EC 2.7.7


Application Date


Grant Date



Related Topics

Molecular biology, DNA replication, Small nuclear RNA, Biotechnology, EC 2.7.7



NOXXON Pharma Web Traffic

Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

NOXXON Pharma Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.